Alta Fundamental Advisers LLC lessened its holdings in shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Free Report) by 46.3% in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,427,479 shares of the company's stock after selling 1,231,110 shares during the quarter. Milestone Pharmaceuticals accounts for about 0.7% of Alta Fundamental Advisers LLC's investment portfolio, making the stock its 17th largest holding. Alta Fundamental Advisers LLC owned approximately 2.67% of Milestone Pharmaceuticals worth $1,142,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. XTX Topco Ltd grew its position in Milestone Pharmaceuticals by 52.7% in the first quarter. XTX Topco Ltd now owns 52,004 shares of the company's stock valued at $42,000 after acquiring an additional 17,950 shares in the last quarter. National Bank of Canada FI boosted its stake in shares of Milestone Pharmaceuticals by 163.4% during the 4th quarter. National Bank of Canada FI now owns 18,700 shares of the company's stock valued at $44,000 after buying an additional 11,600 shares during the last quarter. Cubist Systematic Strategies LLC purchased a new position in shares of Milestone Pharmaceuticals during the 4th quarter valued at approximately $73,000. Northern Trust Corp boosted its stake in shares of Milestone Pharmaceuticals by 112.6% during the 4th quarter. Northern Trust Corp now owns 58,108 shares of the company's stock valued at $137,000 after buying an additional 30,772 shares during the last quarter. Finally, Boxer Capital Management LLC purchased a new position in shares of Milestone Pharmaceuticals during the 4th quarter valued at approximately $729,000. Institutional investors and hedge funds own 86.18% of the company's stock.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright upgraded Milestone Pharmaceuticals to a "buy" rating and set a $5.00 target price for the company in a research note on Thursday, June 5th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $7.00.
Check Out Our Latest Report on MIST
Milestone Pharmaceuticals Stock Down 3.2%
Shares of Milestone Pharmaceuticals stock traded down $0.06 on Thursday, hitting $1.69. 1,220,166 shares of the company's stock traded hands, compared to its average volume of 1,750,290. The stock has a market cap of $90.08 million, a P/E ratio of -2.00 and a beta of 0.52. The company has a quick ratio of 4.67, a current ratio of 4.67 and a debt-to-equity ratio of 4.06. The firm's 50-day moving average is $1.72 and its 200 day moving average is $1.60. Milestone Pharmaceuticals Inc. has a 52-week low of $0.63 and a 52-week high of $2.75.
Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.02). Equities analysts anticipate that Milestone Pharmaceuticals Inc. will post -0.62 earnings per share for the current year.
Milestone Pharmaceuticals Profile
(
Free Report)
Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.
Further Reading
Before you consider Milestone Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Milestone Pharmaceuticals wasn't on the list.
While Milestone Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
